Pipeline

Program
Drug Candidate
Pre-Clinical Testing
IND-Enabling Studies
Phase 1
Gene Therapy
CO-sTiRNA
B-cell Non-Hodgkin's Lymphoma
CO-sTiRNA
+
Checkpoint Inhibitors
and/or
CAR-Ts
B-cell Non-Hodgkin's Lymphoma
Cutaneous T-cell Lymphoma
Other Solid Tumors
CB1R Inverse Agonists
MRI-1867
Systemic Sclerosis
Program
Drug Candidate
Pre-Clinical Testing
IND-Enabling Studies
Phase 1
Gene Therapy
CpG-STAT3siRNA
B-cell Non-Hodgkin's Lymphoma
B-cell Non-Hodgkin's Lymphoma
CpG-STAT3siRNA
+
Checkpoint Inhibitors
and/or
CAR-Ts
Cutaneous T-cell Lymphoma
 
Melanoma
CB1R Inverse Agonists
MRI-1867
Systemic Sclerosis
Drug Candidate
Lead Selection
Pre-Clinical Testing
IND-Enabling Studies
Phase I
Phase II
Phase III
Gene Therapy
B-Cell Lymphoma
T-Cell Lymphoma
MRI-1867
Systemic Sclerosis (Orphan Drug Indication)